AAIC 2025 Abstract·23 DecGABriella, a Phase 2a study investigating the gamma‐secretase modulator RG6289 in individuals at risk for and at the prodromal stage of Alzheimer’s disease: baseline characteristics of the recruited participantsTrial in peoplePopulationsPaper